Last year was a bumper one for biotech IPOs: 81 companies raised $13.5 billion, says SVB Leerink, a US bank with a focus on healthcare and life sciences. The bulk of the funding went to developers of new cancer drugs, which made up 52% of the deal flow and 64% of the capital raised.

To learn more about the economics behind next-generation therapeutic investments, WiC sat down with Simone Song, founder of Hong Kong-based healthcare venture capital firm ORI Capital. Since launching her first healthcare investment vehicle in 2015, Song has had two blockbuster exits through trade sales and is backing another firm that listed on Nasdaq. Her second fund, doubling the size of its predecessor to $400 million, reached its first close early last month.

Click here to read the Q&A.

Best regards,

Steven Irvine, Editor